Company Information

  

Address: 6300 DUMBARTON CIRCLE  
City: FREMONT 
State: CA 
Zip Code: 94555 
Telephone: 510-456-3805 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

We are a clinical-stage biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer. We have industry-leading technology in two cell types, each with broad potential applicability: (1) oligodendrocyte progenitor cells, which become oligodendrocytes that have the potential to remyelinate axons within the central nervous system and perform other restorative functions, and (2) antigen-presenting dendritic cells, which train T-cells in the immune system to attack and destroy solid or liquid tumor cells across multiple types of cancer.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2018-0.42NAN/E
03/2018-0.47NAN/E
12/2017-0.56NAN/E
09/2017-0.64NAN/E
06/2017-0.75NAN/E
03/2017-0.69NAN/E
12/2016-0.83NAN/E
09/2016-0.76NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.19Total Liab/Total Assets0.22
Net Inc/Total Assets-0.66Total Liab/Inv Cap0.24
Net Inc/Inv Cap-0.73Total Liab/Comm Equity0.06
Pretax Inc/Net Sales-7.02Interest Coverage Ratio-60.02
Net Inc/Net Sales-7.02Curr Debt/Equity0.02
Cash Flow/Net Sales-6.05LTD/Equity0.09
SG&A/NetSales2.59Total Debt/Equity0.10
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio6.45
Inventory TurnoverNACurrent Ratio6.45
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work Cap0.21Inv/Curr AssetsNA
Net Sales/PP&E0.89  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) 0.11 0.48 0.03 1.69
Cost of Goods Sold 0.06 0.06 0.01 0.08
Selling & Admin Exps 1.99 1.91 2.13 2.05
Operating Income -5.55 -5.12 -8.55 -7.06
Interest Exp 0.10 0.11 0.11 0.11
Pretax Income -6.98 -2.31 -6.55 -6.81
Other Income -1.34 2.92 2.11 0.37
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -6.98 -2.31 -6.55 -6.81

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 14.81 18.80 21.60 20.72
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 15.89 19.95 22.72 21.93
Net Property, Plant & Equipment 4.03 4.28 4.54 4.76
Total Assets 34.34 39.33 43.09 43.32
Liabilities        
Accounts Payable 1.83 1.38 2.96 2.37
Debt in Current Liabilities 0.60 0.58 0.56 0.01
Total Current Liabilities 2.43 1.96 3.52 2.38
Long-Term Debt 2.64 2.80 2.96 3.64
Total Liabilities 6.27 6.32 9.55 11.59
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -127.81 -120.83 -112.10 -105.55
Treasury Stock NA NA NA NA
Total Stockholders' Equity 28.07 33.00 33.54 31.73
Total Liabilities and Stockholders' Equity 34.34 39.33 43.09 43.32

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities -3.19 -3.94 -5.79 -4.52
Net Cash Provided by Investing Activities 1.00 1.48 0.68 0.12
Net Cash Provided by Financing Activities 0.99 -0.29 9.75 1.15

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-22.38--
12/20141.22-10.10-0.33
12/20153.58-15.00-0.42
12/20166.95-35.49-0.83
12/20174.04-28.37-0.56
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18859,84717.74




Report Date : 9/24/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.